Northern Trust’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-687,426
| Closed | -$7.7M | – | 4322 |
|
|
2017
Q3 | $7.7M | Sell |
687,426
-162,203
| -19% | -$1.79M | ﹤0.01% | 2358 |
|
|
2017
Q2 | $9.35M | Buy |
849,629
+44,095
| +5% | +$441K | ﹤0.01% | 2221 |
|
|
2017
Q1 | $7.89M | Buy |
805,534
+18,609
| +2% | +$186K | ﹤0.01% | 2277 |
|
|
2016
Q4 | $8.5M | Buy |
786,925
+11,941
| +2% | +$119K | ﹤0.01% | 2220 |
|
|
2016
Q3 | $7.94M | Sell |
774,984
-2,999
| -0.4% | -$32.7K | ﹤0.01% | 2216 |
|
|
2016
Q2 | $10.2M | Buy |
777,983
+1,003
| +0.1% | +$13.1K | ﹤0.01% | 2014 |
|
|
2016
Q1 | $8.55M | Buy |
776,980
+40,162
| +5% | +$357K | ﹤0.01% | 2076 |
|
|
2015
Q4 | $6.78M | Buy |
736,818
+12,548
| +2% | +$105K | ﹤0.01% | 2260 |
|
|
2015
Q3 | $5.03M | Buy |
724,270
+67,880
| +10% | +$581K | ﹤0.01% | 2440 |
|
|
2015
Q2 | $6.45M | Buy |
656,390
+70,008
| +12% | +$638K | ﹤0.01% | 2352 |
|
|
2015
Q1 | $5.2M | Buy |
586,382
+23,647
| +4% | +$188K | ﹤0.01% | 2483 |
|
|
2014
Q4 | $4.93M | Sell |
562,735
-22,278
| -4% | -$180K | ﹤0.01% | 2519 |
|
|
2014
Q3 | $4.03M | Sell |
585,013
-42,387
| -7% | -$254K | ﹤0.01% | 2651 |
|
|
2014
Q2 | $3.3M | Sell |
627,400
-87,487
| -12% | -$426K | ﹤0.01% | 2795 |
|
|
2014
Q1 | $3.25M | Sell |
714,887
-75,579
| -10% | -$365K | ﹤0.01% | 2833 |
|
|
2013
Q4 | $3.98M | Sell |
790,466
-51,693
| -6% | -$249K | ﹤0.01% | 2716 |
|
|
2013
Q3 | $4.27M | Buy |
842,159
+1,855
| +0.2% | +$10.3K | ﹤0.01% | 2615 |
|
|
2013
Q2 | $4.17M | Buy |
+840,304
| New | +$4M | ﹤0.01% | 2543 |
|
Northern Trust's SCLN Position: Q4 2017 in Review
Northern Trust sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 687,426 shares — an estimated $7.7M sold.
Northern Trust first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $10.2M in Q2 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Northern Trust reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Northern Trust sold 687,426 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $7.7M.
- Northern Trust first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Northern Trust's Sciclone Pharmaceuticals Inc position peaked at $10.2M in Q2 2016.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Northern Trust's 13F filing for Q4 2017, filed 14 Feb 2018.